Aarti Pharmalabs share price today

Aarti Pharmalabs Ltd's share price was ₹926.50 at the close on 4 November 2026. It has been rising for 10 weeks. That is 18.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹609 and ₹969, and at that close it sat 88% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Aarti Pharmalabs Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 15 weeks in a row.

Over the last 3.8 years the share price moved +257% while the NIFTY 500 moved +46%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: promoters cut their stake for 3 quarters in a row, highest quarterly revenue in 16 quarters and operating margin up 4 points on a year earlier.

1. Promoters cut their stake for 3 quarters in a row

   From 43.1% to 39.7% of the company by the September 2026 quarter.

2. Highest quarterly revenue in 16 quarters

   Revenue of ₹610 crore in the September 2026 quarter is the highest of the last 16 quarters.

   Why: Revenue hit a record because the steroid plant restarted after a shutdown and restored sales that had been held up.

   Next results: check whether the new Atali block starts making sales after it is set up.

   From the earnings call on 29 Oct 2026.

3. Operating margin up 4 points on a year earlier

   22% in the September 2026 quarter, from 18%.

   Why: Margins improved because the company sold more CDMO work, which carries higher profit.

   Next results: check whether higher CDMO sales cover new plant costs.

   From the earnings call on 29 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Aarti Pharmalabs reported revenue of ₹610 crore, up 45.9% from ₹418 crore a year earlier, and a profit of ₹71.0 crore, up 153.6% from ₹28.0 crore.

Aarti Pharmalabs results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Aarti Pharmalabs' management discussed these results on a call held on 29 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Aarti Pharmalabs closed at ₹926.50 on 4 November 2026, up 7.1% from ₹864.95 a year earlier (7 November 2025) and up 136.7% over three years. Its highest weekly close since February 2023 was ₹968.50 on 1 October 2026.

Aarti Pharmalabs share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

201 weekly closes from 3 February 2023 to 4 November 2026.

4 Nov 2026: Aarti Pharmalabs closed at ₹926.50, up 6.2% on the week and down 4.3% on the month. 29 Oct 2026: Aarti Pharmalabs held its results call for July to September 2026. Management guided: CDMO revenue growth 40-50% over last year for FY27.

Earlier

• Results for July to September 2026: Revenue up 45.9% and profit up 153.6% on a year earlier.
• 15 Sep 2026: ex-date for a dividend of ₹2 a share.
• 16 Feb 2026: ex-date for an interim dividend of ₹1.50 a share.

Aarti Pharmalabs paid ₹3.50 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 0.38% at the ₹926.50 close on 4 November 2026. The last was a dividend of ₹2 a share, ex-date 15 September 2026.

Aarti Pharmalabs dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Aarti Pharmalabs Ltd paid out 18% of its profit as dividends in FY26, and it paid a dividend in 4 of its last 5 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 29 October 2026, Aarti Pharmalabs' management guided: CDMO revenue growth 40-50% over last year for FY27.

“We remain on track to achieve our target of 40%-50% revenue growth over last year in this business segment.”Rashesh Gogri, on the call for July to September 2026

What management guided

• Xanthine volumes about 7,000 tonnes now to 7,500-8,000 tonnes next year and about 8,800 tonnes in two years for 15-20% growth this year.
• Xanthine revenue ₹1,400-1,500 crore at full capacity if prices stay high with pass-through lowering top line if costs fall.
• API plus intermediates ₹180-200 crore per quarter in second half with 10-15% annual growth from volume and new products.
• CDMO ₹1,000 crore or $100 million aspiration with 10-12 projects driving ₹700-800 crore, timing plus-minus one year.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 29 October 2026.

When Aarti Pharmalabs reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: CDMO second-half conversion pace implied by maintained full-year growth goal - quarterly print shows whether lumpiness resolves.

Aarti Pharmalabs is on 2 of our India lists: Momentum stocks and Pharma stocks.

Aarti Pharmalabs Ltd earned ₹71.0 Cr of net profit in the Sep 2026 quarter, +153.6% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹175 Cr. That is 11.6% of the quarter's revenue. The same quarter a year earlier earned ₹28.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹175 Cr (−35.7% on the year before).

Why profit moved: revenue changed +45.9% on a year earlier and the margin moved +4.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +35.0% and revenue +17.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Aarti Pharmalabs Ltd reported ₹610 Cr of revenue in the Sep 2026 quarter, +45.9% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. The last full year, FY26, came in at ₹1,819 Cr. The last four reported quarters add to ₹2,161 Cr.

Revenue is everything the company billed its customers in the period.

A growth rate over several years is not shown, because there are too few years of figures to work one out properly.

FY26 revenue was ₹1,819 Cr, −14.0% on the year before.

Is growth speeding up? Revenue over the last 12 months grew +13.4%, against +4.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +6.7%, against +6.0% a year (stabilising).

Aarti Pharmalabs Ltd's operating margin was 22.0% in the Sep 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Across 5 years it has been between 17.0% and 22.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +4.4 percentage points on the year while gross margin changed +1.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 122% of Aarti Pharmalabs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹262 Cr of operating cash against ₹175 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹423 Cr of spending on assets, free cash was −₹161 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 122% of profit came in as cash: the cash cycle got 13 days shorter between FY22 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 4.0× depreciation over three years. The next section checks what that spending is building.

Aarti Pharmalabs Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 251 days in FY26, down from 264 days in FY22. It spent ₹1,066 Cr on assets over the last 3 years. Customers take 117 days to pay, and stock sits for 280 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,819 Cr, each day of that cycle ties up about ₹5.0 Cr, so roughly ₹1,251 Cr is tied up in the business at any time.

FY26: customers took 117 days to pay and stock sat for 280 days, about 9.2 months of sales sitting as stock, for a full cycle of 251 days, shorter than FY22's 264.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 280 days. Customers pay about 117 days after that. Suppliers are paid at 146 days. Together that makes the 251-day cycle.

Spending on assets: ₹1,066 Cr over the last 3 years, against ₹264 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹393 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Aarti Pharmalabs Ltd's P/E is 32.3×, near the high end of its own history: higher than 89% of past readings. Its usual P/E (the middle reading) is 26.7×, over 3.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹28.31.

Why the multiple is where it is: over the past year earnings per share moved −35.9% while the price moved +7.1%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 3 years the price moved +33.3% a year; about +10.3% a year came from earnings growth and about +23.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Aarti Pharmalabs Ltd's business is giving mixed signals. Growth has been steadily positive, but ROCE at 14.1% is below the 15% level needed to call it steady growth. This is based on 11 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Aarti Pharmalabs Ltd earned a ROCE of 11% in FY26. Its return on capital used (ROIC) is 3.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 9.6% net margin and 0.52× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 9.6% net margin × 0.52× asset turnover × 1.64× leverage (assets divided by equity) ≈ 8.2% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 8.5% − 12.0% = −3.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Aarti Pharmalabs Ltd has total debt of ₹794 Cr against shareholder equity of ₹2,125 Cr as of Jun 2026, so its debt is 0.37× its equity. Year by year, that ratio went from 0.25 in FY22 to 0.36 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Promoters cut their stake in Aarti Pharmalabs Ltd by 6.4 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 39.7% of the company. Domestic institutions moved −2.9 points over the same period, to 8.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: −6.4 points over 8 quarters, to 39.7%; Domestic institutions: −2.9 points over 8 quarters, to 8.4%; Foreign institutions: +0.8 points over 8 quarters, to 8.2%.

Why the owners changed: promoters drove it (−6.4 points), together with domestic institutions (−2.9 points). They reduced their stake.

For Aarti Pharmalabs Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

44.9 out of 100, rank 10 of 14 in Pharma - API, with 85% of the evidence available.

Aarti Pharmalabs Ltd scores 44.9 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 10. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 17.8 + 12.4 + 2.9 + 11.8 = 44.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Aarti Pharmalabs ranks 10 of 14 Pharma - API companies on the 4-Factor Sector Score, with 44.9 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - API, all 14 compared on one page.

Aarti Pharmalabs is the largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: Innova Captab, Senores Pharmaceuticals, Orchid Pharma, Gujarat Themis Biosyn, Aarti Drugs and Ind-Swift Laboratories.

Pharma - API companies close in size

1. Aarti Pharmalabs Ltd ₹7,914 crore
2. Innova Captab Ltd ₹5,867 crore
3. Senores Pharmaceuticals Ltd ₹5,222 crore
4. Orchid Pharma Ltd ₹5,009 crore
5. Gujarat Themis Biosyn Ltd ₹4,727 crore
6. Aarti Drugs Ltd ₹3,972 crore
7. Ind-Swift Laboratories Ltd ₹3,202 crore

All 14 Pharma - API companies, largest first

Companies close in size in other industries

652. Sudarshan Chemical Industries Ltd ₹7,930 crore · Dyes & Pigments
653. Sanofi Consumer Healthcare India Ltd ₹7,925 crore · Pharma - MNC bulk Drugs
654. Aarti Pharmalabs Ltd ₹7,914 crore
655. KRBL Ltd ₹7,898 crore · FMCG - Rice
656. Standard Engineering Technology Ltd ₹7,897 crore · Engineering - Heavy - Glass - lined Equipment

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.